VCD-D Study (AMaRC 16-03)

A randomized phase 2 study of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma.

The primary purpose of this trial is to assess whether the addition of datatumumab to a velcade, cyclophosphamide and dexamethasone treatment regime will cause an improvement in disease progression free survival.

For more information please visit

Project Information

Institution:

Australasian Myeloma Research Consortium (AMaRC C/- Alfred Health)

Specialities:

Haematology

Oncology

Other (specify below)

End date:

​

Can this be done remotely?

​

Suitability:

​

Parts of research done:

Literature review, Research proposal, Ethics approval

Positions Available:

Data Collector

Statistician

​

Current Funding:

Janssen

​

Prospective researchers receive:

​

Website

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=372260&isReview=true

​

Project owner

Peter Mollee

Please fill out the form below to express your interest in this research project. It is free to contact a project owner and express interest in a project. We recommend writing a detailed message regarding why you are interested in the project (e.g. what skills you can bring to the team) or what information you are seeking (e.g. detail regarding the study duration). All information you provide will be shared with the primary researcher, including your contact details. Thank you for your interest in this project.